论文部分内容阅读
为了确定4-去甲氧柔红霉素(Idarubicin)和柔红霉素(DNR)治疗急性髓细胞白血病(AML)的价值,作者将32个研究单位的214例初治成人(≥15岁)AML 随机分为二组进行治疗。两组病人在年龄、一般状况、血象、白血病类型、感染及出血方面均相似。其诱导方案分别为:Ara-C100mg/m~2/d,静脉持续滴注7天,加DNR45mg/m~2/d 前三天静脉推注A+D组;或加4-去甲氧柔红霉素13mg/m~2/d,前三天静脉推注A+I 组。未获CR 的病人再进行第二疗程治疗(剂量同第一疗程)。缓解后用原方案剂量巩固2个疗程,但蒽环类抗生素改用2天,Ara-C 改用5天。
To determine the value of Idarubicin and daunorubicin (DNR) in the treatment of acute myeloid leukemia (AML), the authors treated 214 untreated adults (≥15 years of age) in 32 study units. AML is randomly divided into two groups for treatment. Both groups were similar in terms of age, general condition, hemogram, leukemia type, infection, and bleeding. The induction program was: Ara-C100mg/m~2/d, continuous intravenous infusion for 7 days, plus DNR 45mg/m~2/d three days before the intravenous injection of A + D group; or 4- to methoxyl Erythromycin 13mg/m~2/d, the first three days of intravenous injection of A + I group. Patients who did not receive CR were given a second course of treatment (the dose was the same as the first course of treatment). After remission, 2 doses were consolidated with the original regimen, but anthracycline was switched to 2 days, and Ara-C was changed to 5 days.